Treating MERS-CoV during an outbreak (Q41718128)

8 October 2017

title

Treating MERS-CoV during an outbreak (English)

1 reference

Middle East respiratory syndrome coronavirus

8 October 2017

main subject

0 references

author

Christopher M Coleman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Matthew B Frieman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

29 September 2014

1 reference

Lancet Infectious Diseases

8 October 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1030-1031

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Respiratory syncytial virus: current and emerging treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Treatment of hantavirus pulmonary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

New opportunities for field research on the pathogenesis and treatment of Lassa fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970939-9

7 January 2021

10.1016/S1473-3099(14)70939-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25278219%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference